Historical record - last NADAC publication: 1/15/2019
Product Information
EXFORGE HCT 10-160-25 MG TAB is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $9.7743 per EA under NDC 00078056215. Its NADAC has been published 314 times since Nov 28, 2013.
Strength
10; 25; 160 mg/1; mg/1; mg/1
Manufacturer
Novartis Pharmaceuticals CorporationNDC
00078056215
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Last Updated
1/15/2019
Active Ingredients
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTANApproval Type
New Drug (NDA)
FDA Application
NDA022314On Market Since
4/4/2009
Pharmacological Classes
Price Statistics
The NADAC for EXFORGE HCT 10-160-25 MG TAB has been published 314 times since Nov 28, 2013, and over the history we have for it it has risen 103.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $9.7743 per EA |
|---|---|
| All-time high | $9.7743 (Jan 15, 2020) |
| All-time low | $4.8159 (Nov 28, 2013) |
| Median price | $8.0577 |
| Average price | $7.7782 |
| Largest weekly change | +19.5% (Apr 15, 2015) |
| Weeks tracked | 314 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient, strength, and dosage form. Compare the broader picture on the amlodipine valsartan and hydrochlorothiazide market page.
Lowest-Cost Alternatives
No alternatives available
Frequently asked questions
What is the NADAC price of EXFORGE HCT 10-160-25 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for EXFORGE HCT 10-160-25 MG TAB, manufactured by Novartis Pharmaceuticals Corporation, is $9.7743 per EA (NDC 00078056215), effective Jan 15, 2020.
How has the price of EXFORGE HCT 10-160-25 MG TAB changed over time?
Over the history we have for it, the NADAC for EXFORGE HCT 10-160-25 MG TAB has risen 103.0%. It has been tracked across 314 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for EXFORGE HCT 10-160-25 MG TAB?
Since Nov 28, 2013, the NADAC for EXFORGE HCT 10-160-25 MG TAB has ranged from a low of $4.8159 (Nov 28, 2013) to a high of $9.7743 (Jan 15, 2020), with a median of $8.0577 per EA.
Are there cheaper alternatives to EXFORGE HCT 10-160-25 MG TAB?
No other NADAC-published product currently shares the active ingredient, strength, and dosage form of EXFORGE HCT 10-160-25 MG TAB, so no direct lower-cost alternative is listed.
Who manufactures EXFORGE HCT 10-160-25 MG TAB?
EXFORGE HCT 10-160-25 MG TAB (NDC 00078056215) is labeled by Novartis Pharmaceuticals Corporation, and CMS classifies it as a brand product.
Related Drugs
Same classification